Almac Diagnostic Services to Develop Companion Diagnostic for TP Therapeutics' Cancer Drug

TP Therapeutics announced on 10/24/18 a global collaboration agreement to develop and commercialize a next-generation sequencing (NGS) companion diagnostic (CDx) for repotrectinib, TP Therapeutics’ investigational therapy rationally designed to target ROS1, NTRK1-3 and ALK gene fusions in advanced solid tumors.